Kisqali(r) shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
October 23, 2026
October 23, 2026
BASEL, Switzerland, Oct. 23 [Category: BizPharmaceuticals] -- Novartis, a pharmaceutical company, posted the following news release:
* * *
Kisqali(r) shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
*
* Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1
* Benefit increased over time in invasive disease-free survival and a . . .
* * *
Kisqali(r) shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
*
* Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1
* Benefit increased over time in invasive disease-free survival and a . . .